How I treat patients who are refractory to platelet transfusions Available to Purchase

2.

Hod

E

,

Schwartz

J

.

Platelet transfusion refractoriness

.

Br J Haematol

.

2008

;

142

(

3

):

348

-

360

.

3.

Delaflor-Weiss

E

,

Mintz

PD

.

The evaluation and management of platelet refractoriness and alloimmunization

.

Tranfus Med Rev

.

2000

;

14

(

2

):

180

-

196

.

4.

Pavenski

K

,

Freedman

J

,

Semple

JW

.

HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management

.

Tissue Antigens

.

2012

;

79

(

4

):

237

-

245

.

5.

Juskewitch

JE

,

Norgan

AP

,

De Goey

SR

, et al.

How do I … manage the platelet transfusion-refractory patient?

.

Transfusion

.

2017

;

57

(

12

):

2828

-

2835

.

6.

Trial to Reduce Alloimmunization to Platelets Study Group

.

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

.

N Engl J Med

.

1997

;

337

(

26

):

1861

-

1869

.

7.

Kelly

AM

,

Garner

SF

,

Foukaneli

T

, et al.

The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial

.

Blood

.

2017

;

130

(

2

):

214

-

220

.

8.

Gottschall

J

,

Wu

Y

,

Triulzi

D

, et al.

The epidemiology of platelet transfusions: an analysis of platelet use at 12 US hospitals

.

Transfusion

.

2020

;

60

(

1

):

46

-

53

.

9.

Anthon

CT

,

Pène

F

,

Perner

A

, et al.

Platelet transfusions in adult ICU patients with thrombocytopenia: A sub-study of the PLOT-ICU inception cohort study

.

Acta Anaesthesiol Scand

.

2024

;

68

(

8

):

1018

-

1030

.

10.

Curley

A

,

Stanworth

SJ

,

Willoughby

K

, et al.

Randomized trial of platelet-transfusion thresholds in neonates

.

N Engl J Med

.

2019

;

380

(

3

):

242

-

251

.

11.

Stanworth

SJ

,

Clarke

P

,

Watts

T

, et al.

Prospective, observational study of outcomes in neonates with severe thrombocytopenia

.

Pediatrics

.

2009

;

124

(

5

):

e826

-

e834

.

12.

Arabi

S

,

Almahayni

AO

,

Alomair

AA

,

Masuadi

EM

,

Damlaj

M

,

Al-Dorzi

HM

.

Prevalence, risk factors, and outcomes of platelet transfusion refractoriness in critically ill patients: a retrospective cohort study

.

Crit Care Res Pract

.

2021

;

2021

:

5589768

.

13.

Comont

T

,

Tavitian

S

,

Bardiaux

L

, et al.

Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy

.

Leuk Res

.

2017

;

61

:

62

-

67

.

14.

Kerkhoffs

JL

,

Eikenboom

JC

,

van de Watering

LM

,

van Wordragen-Vlaswinkel

RJ

,

Wijermans

PW

,

Brand

A

.

The clinical impact of platelet refractoriness: correlation with bleeding and survival

.

Transfusion

.

2008

;

48

(

9

):

1959

-

1965

.

15.

Stanworth

SJ

,

Navarrete

C

,

Estcourt

L

,

Marsh

J

.

Platelet refractoriness-practical approaches and ongoing dilemmas in patient management

.

Br J Haematol

.

2015

;

171

(

3

):

297

-

305

.

16.

Hagino

T

,

Sato

T

,

Tsuno

NH

,

Tasaki

T

.

Incidence and management of non-immune platelet transfusion refractoriness: a narrative review

.

Ann Blood

.

2021

;

6

:

28

.

17.

Youk

HJ

,

Hwang

SH

,

Oh

HB

,

Ko

DH

.

Evaluation and management of platelet transfusion refractoriness

.

Blood Res

.

2022

;

57

(

suppl 1

):

6

-

10

.

18.

Hess

JR

,

Trachtenberg

FL

,

Assmann

SF

, et al.

Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial

.

Vox Sang

.

2016

;

111

(

3

):

281

-

291

.

19.

Saris

A

,

Pavenski

K

.

Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness

.

Transfus Med Rev

.

2020

;

34

(

4

):

250

-

257

.

20.

Daly

PA

,

Schiffer

CA

,

Aisner

J

,

Wiernik

PH

.

One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations

.

JAMA

.

1980

;

243

(

5

):

435

-

438

.

21.

Slichter

SJ

,

Davis

K

,

Enright

H

, et al.

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients

.

Blood

.

2005

;

105

(

10

):

4106

-

4114

.

22.

Slichter

SJ

,

Bolgiano

D

,

Kao

KJ

, et al.

Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products

.

Transfus Med Rev

.

2011

;

25

(

2

):

102

-

110

.

23.

Evers

D

,

Zwaginga

JJ

,

Tijmensen

J

, et al.

Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization

.

Haematologica

.

2017

;

102

(

1

):

52

-

59

.

24.

Peña

JR

,

Saidman

SL

,

Girouard

TC

,

Meister

E

,

Dzik

WH

,

Makar

RS

.

Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion

.

Am J Hematol

.

2014

;

89

(

9

):

E133

-

E137

.

25.

Murphy

MF

,

Metcalfe

P

,

Ord

J

,

Lister

TA

,

Waters

AH

.

Disappearance of HLA and platelet specific antibodies in acute leukaemia patients alloimmunized by multiple platelet transfusions

.

Br J Haematol

.

1987

;

67

(

3

):

255

-

260

.

26.

Kleinman

S

,

King

MR

,

Busch

MP

, et al.

The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability

.

Transfus Med Rev

.

2012

;

26

(

4

):

281

-

304. 304e1-2

.

27.

Seftel

MD

,

Growe

GH

,

Petraszko

T

, et al.

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness

.

Blood

.

2004

;

103

(

1

):

333

-

339

.

28.

Cardillo

A

,

Heal

JM

,

Henrichs

K

, et al.

Reducing the need for HLA-matched platelet transfusion

.

N Engl J Med

.

2021

;

384

(

25

):

2451

-

2452

.

29.

Scherlinger

M

,

Richez

C

,

Tsokos

GC

,

Boilard

E

,

Blanco

P

.

The role of platelets in immune-mediated inflammatory diseases

.

Nat Rev Immunol

.

2023

;

23

(

8

):

495

-

510

.

30.

Panch

SR

,

Guo

L

,

Vassallo

R

.

Platelet transfusion refractoriness due to HLA alloimmunization: evolving paradigms in mechanisms and management

.

Blood Rev

.

2023

;

62

:

101135

.

31.

Chen

X

,

Zhao

Y

,

Lv

Y

,

Xie

J

.

Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics

.

Platelets

.

2024

;

35

(

1

):

2306983

.

32.

Belizaire

R

,

Makar

RS

.

Non-alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion

.

Transfus Med Rev

.

2020

;

34

(

4

):

242

-

249

.

33.

Takahashi

D

,

Nakajima

F

,

Tsuno

NH

.

Human leukocyte antigen antibody detection techniques in platelet transfusion refractoriness, with special emphasis of functional test

.

Ann Blood

.

2018

;

3

:

42

.

34.

Blandin

L

,

Dougé

A

,

Fayard

A

, et al.

Platelet transfusion refractoriness and anti-HLA immunization

.

Transfusion

.

2021

;

61

(

6

):

1700

-

1704

.

35.

Pedini

P

,

Hubert

L

,

Baudey

J-B

, et al.

Comparison of HLA antibody identification methods for the selection of platelet products for HLA-mediated platelet refractory patients

.

HLA

.

2024

;

103

(

1

):

e15276

.

36.

Beligaswatte

A

,

Tsiopelas

E

,

Humphreys

I

, et al.

The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness

.

Br J Haematol

.

2013

;

162

(

3

):

409

-

412

.

37.

Boothby

AB

,

Tanner

MK

,

Alswied

A

, et al.

Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients

.

Blood Adv

.

2024; 10

;

8

(

17

):

4689

-

4699

.

38.

Anthon

CT

,

Pène

F

,

Perner

A

, et al.

Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU) [published correction appears in Intensive Care Med. 2024;50(1):154-155]

.

Intensive Care Med

.

2023

;

49

(

11

):

1327

-

1338

.

39.

Narayan

S

, et al.

The 2023 Annual SHOT Report, Manchester: Serious Hazards of Transfusion (SHOT) Steering Group

. 2024. Accessed 27 June 2024. https://doi.org/10.57911/605r-em59.

40.

Baharoglu

MI

,

Cordonnier

C

,

Al-Shahi Salman

R

, et al.

Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial

.

Lancet

.

2016

;

387

(

10038

):

2605

-

2613

.

41.

Chen

BZ

,

Xia

R

.

Pro-inflammatory effects after platelet transfusion: a review

.

Vox Sang

.

2020

;

115

(

5

):

349

-

357

.

42.

Garraud

O

,

Cognasse

F

.

Are platelets cells? And if yes, are they immune cells?

.

Front Immunol

.

2015

;

6

(

6

):

70

.

43.

Yan

C

,

Wu

H

,

Fang

X

,

He

J

,

Zhu

F

.

Platelet, a key regulator of innate and adaptive immunity

.

Front Med

.

2023

;

10

:

1074878

.

44.

Chu

YH

,

Rose

WN

,

Nawrot

W

,

Raife

TJ

.

Pooled platelet concentrates provide a small benefit over single-donor platelets for patients with platelet refractoriness of any etiology

.

J Int Med Res

.

2021

;

49

(

5

):

3000605211016748

.

45.

Narvios

A

,

Reddy

V

,

Martinez

F

,

Lichtiger

B

.

Slow infusion of platelets: a possible alternative in the management of refractory thrombocytopenic patients

.

Am J Hematol

.

2005

;

79

(

1

):

80

.

46.

Carter

J

,

Szymanski

J

,

Cantilena

C

,

Adams

S

,

Sahu

S

,

Flegel

WA

.

Continuous platelet transfusion as a potential desensitization regimen in HLA class I alloimmune mediated platelet refractoriness [abstract]

.

Blood

.

2017

;

130

(

suppl 1

):

4925

.

47.

Kreuger

AL

,

Mäkelburg

ABU

,

Somers

JAE

, et al.

HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening

.

Transfusion

.

2019

;

59

(

11

):

3303

-

3307

.

48.

Stanworth

SJ

,

Shah

A

.

How I use platelet transfusions

.

Blood

.

2022

;

140

(

18

):

1925

-

1936

.

49.

Gernsheimer

TB

,

Brown

SP

,

Triulzi

DJ

, et al.

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial

.

Blood

.

2022

;

140

(

11

):

1254

-

1262

.

50.

Estcourt

LJ

,

McQuilten

Z

,

Powter

G

, et al.

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

.

Lancet Haematology

.

2025

;

12

(

1

):

e14

-

e22

.

51.

Schmidt

AE

,

Refaai

MA

,

Coppage

M

.

HLA-mediated platelet refractoriness

.

Am J Clin Pathol

.

2019

;

151

(

4

):

353

-

363

.

52.

Kopko

PM

,

Warner

P

,

Kresie

L

,

Pancoska

C

.

Methods for the selection of platelet products for alloimmune-refractory patients

.

Transfusion

.

2015

;

55

(

2

):

235

-

244

.

53.

Salama

OS

,

Aladl

DA

,

El Ghannam

DM

,

Elderiny

WE

.

Evaluation of platelet cross-matching in the management of patients refractory to platelet transfusions

.

Blood Transfus

.

2014

;

12

(

2

):

187

-

194

.

54.

Neanaey

WA

,

Deghady

AA

,

Nafea

DA

,

Fahmy

NM

,

Gouda

AM

.

Evaluation of human leucocyte antigen mediated platelet transfusion refractoriness and platelet crossmatching assay in patients with hematologic disorders

.

Oman Med J

.

2022

;

37

(

4

):

e402

.

55.

Sinwatcharaphirom

T

,

Apisawes

K

,

Kittivorapart

J

.

Evaluation of the effectiveness of platelet crossmatching by the solid-phase red cell adherence assay in adult patients of a tertiary care hospital in Thailand: a retrospective study

.

Health Sci Rep

.

2022

;

5

(

5

):

e769

.

56.

Sullivan

JC

,

Peña

JR

.

Use of human leukocyte antigen (HLA)-incompatible platelet units in HLA platelet-refractory patients with limited number of or low-level HLA donor-specific antibodies results in permissive transfusions

.

Arch Pathol Lab Med

.

2022

;

146

(

10

):

1243

-

1251

.

57.

Gavva

C

,

Barroso

J

,

Gernsheimer

T

,

Metcalf

RA

,

Warner

P

,

Pagano

MB

.

Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients

.

Transfusion

.

2019

;

59

(

7

):

2276

-

2281

.

58.

Shehata

N

,

Tinmouth

A

,

Naglie

G

,

Freedman

J

,

Wilson

K

.

ABO-identical versus nonidentical platelet transfusion: a systematic review

.

Transfusion

.

2009

;

49

(

11

):

2442

-

2453

.

59.

Karafin

MS

,

Schumacher

C

,

Zhang

J

,

Simpson

P

,

Johnson

ST

,

Pierce

KL

.

Human leukocyte antigen (HLA) incompatible mean fluorescence intensity selected platelet products have corrected count increments similar to HLA antigen-matched platelets

.

Transfusion

.

2021

;

61

(

8

):

2307

-

2316

.

60.

Pavenski

K

,

Rebulla

P

,

Duquesnoy

R

, et al.

Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review

.

Transfusion

.

2013

;

53

(

10

):

2230

-

2242

.

61.

Marsh

JC

,

Stanworth

SJ

,

Pankhurst

LA

, et al.

An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial

.

Blood

.

2021

;

137

(

3

):

310

-

322

.

62.

Kallon

D

,

Navarrete

CV

,

Sage

DA

, et al.

Impact of human leucocyte antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients

.

Transfus Med

.

2020

;

30

(

1

):

23

-

29

.

63.

Duquesnoy

RJ

.

Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?

.

Transfusion

.

2008

;

48

(

2

):

221

-

227

.

64.

Saris

A

,

Tomson

B

,

Brand

A

, et al.

Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization

.

Blood

.

2018

;

131

(

1

):

144

-

152

.

65.

Lee

EJ

,

Schiffer

CA

.

Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients

.

Blood

.

1987

;

70

(

6

):

1727

-

1729

.

66.

Rosenbaum

ER

,

Pandey

S

,

Harville

TO

,

Drobena

GA

,

Cottler-Fox

M

.

Flow cytometric panel-reactive antibody results and the ability to find transfusion-compatible platelets after antibody-desensitization for allogeneic bone marrow transplant

.

Ann Clin Lab Sci

.

2016

;

46

(

6

):

662

-

665

.

67.

Vo

P

,

Purev

E

,

West

KA

, et al.

A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients

.

Br J Haematol

.

2020

;

189

(

3

):

551

-

558

.

68.

Shanwell

A

,

Sallander

S

,

Olsson

I

,

Gulliksson

H

,

Pedajas

I

,

Lerner

R

.

An alloimmunized thrombocytopenic patient successfully transfused with acid-treated random-donor platelets

.

Br J Haematol

.

1991

;

79

(

3

):

462

-

465

.

69.

Mirlashari

MR

,

Vetlesen

A

,

Nissen-Meyer

LSH

, et al.

HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients

.

Transfusion

.

2021

;

61

(

4

):

1222

-

1234

.

70.

Feng

Q

,

Shabrani

N

,

Thon

JN

, et al.

Scalable generation of universal platelets from human induced pluripotent stem cells

.

Stem Cell Rep

.

2014

;

3

(

5

):

817

-

831

.

71.

Uhl

L

,

Assmann

SF

,

Hamza

TH

,

Harrison

RW

,

Gernsheimer

T

,

Slichter

SJ

.

Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial

.

Blood

.

2017

;

130

(

10

):

1247

-

1258

.

72.

Meehan

KR

,

Matias

CO

,

Rathore

SS

, et al.

Platelet transfusions: utilization and associated costs in a tertiary care hospital

.

Am J Hematol

.

2000

;

64

(

4

):

251

-

256

.

73.

Ypma

PF

,

van Geloven

N

,

Kerkhoffs

JLH

, et al.

The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study

.

Br J Haematol

.

2020

;

189

(

1

):

171

-

181

.

74.

Stanworth

SJ

,

Hudson

CL

,

Estcourt

LJ

,

Johnson

RJ

,

Wood

EM

;

TOPPS study investigators

.

Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis

.

Haematologica

.

2015

;

100

(

6

):

740

-

747

.

75.

Murphy

MF

,

Metcalfe

P

,

Thomas

H

, et al.

Use of leucocyte-poor blood components and HLA- matched-platelet donors to prevent HLA alloimmunization

.

Br J Haematol

.

1986

;

62

(

3

):

529

-

534

.